https://www.thebodypro.com/category/pregnancy-childbirth-hiv/tag/conference-coverage

The Latest

pregnant woman talking to doctor

Raltegravir Not Linked to Birth Defects, Study Shows

Amidst uncertainty regarding the safety of some integrase inhibitors during pregnancy, a study shows that an older integrase inhibitor may be a good option for those with HIV who intend to give birth.

Fernanda Fernandes Fonseca and Meg Doherty at an IAS 2019 press conference

World Health Organization Updates Guidance on Dolutegravir After Reassuring Data Regarding Safety in Early Pregnancy

New study results leave many experts feeling they went too far in their concerns over birth defect risks associated with the drug.

Mexico City's Downtown At Twilight

IAS 2019: What to Expect in HIV Science

Six thousand HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.

Dolutegravir More Effective Than Efavirenz at Achieving Viral Suppression During Late-Term Pregnancy, New Study Shows Img

Dolutegravir More Effective Than Efavirenz at Achieving Viral Suppression During Late-Term Pregnancy, New Study Shows

Unlike some previous studies that focused on early pregnancy, this study showed no associated congenital disabilities with either drug.

Research Is Still Exploring Best Treatment Strategies for Pregnant and Breastfeeding Women, Interactions With Contraceptives Img

Research Is Still Exploring Best Treatment Strategies for Pregnant and Breastfeeding Women, Interactions With Contraceptives

Several new studies presented at the annual Conference on Retroviruses and Opportunistic Infections (CROI) underscore the complex ways that HIV risk and treatment adherence manifest among women of childbearing age.

CROI sign and podium

New Study Shows Women's HIV Risk Triples During Pregnancy, Quadruples Postpartum

Study highlights the need for PrEP and other HIV prevention strategies for pregnant women and new mothers in high-prevalence settings.

VRC01 in HIV-Exposed Newborns: First Results Support Monthly Injections for Those at Risk Through Breastfeeding Img

VRC01 in HIV-Exposed Newborns: First Results Support Monthly Injections for Those at Risk Through Breastfeeding

Preliminary results suggest that VRC01 -- an investigational HIV neutralising monoclonal antibody -- administered subcutaneously to neonates is safe and well tolerated.

PREP in Pregnancy Does Not Increase Poor Birth Outcomes Img

PREP in Pregnancy Does Not Increase Poor Birth Outcomes

No increase in poor birth outcomes with PrEP used throughout pregnancy in the Partners Demonstration project.

Adverse Pregnancy Outcomes and Risk Factors in the PROMISE Trial Img

Adverse Pregnancy Outcomes and Risk Factors in the PROMISE Trial

While antiretroviral therapy in pregnancy reduced vertical transmission, it also increased the frequency of several adverse birth outcomes compared with antenatal zidovudine (AZT) alone.

No Increase in Adverse Birth Outcomes With Maternal TDF/FTC in U.S. Study Img

No Increase in Adverse Birth Outcomes With Maternal TDF/FTC in U.S. Study

Among pregnant women with HIV in the PROMISE trial, use of TDF/FTC/LPV/r was not associated with increased risk of adverse infant birth outcomes when compared to AZT/3TC/LPV/r or TDF/FTC/ATV/r.